

CURRICULUM VITAE



Name: Emanuele Buratti

Date of Birth: 27/12/1965

Place of Birth: Torino (TO), Italy

Nationality: Italian

Residence: Via Bonomea 108/19
Trieste, Italy
Tel. (house): +39-40-414601
Tel. (mobile): +39-3927439374.

Marital status: married

Children: Francesco (M), born 28/08/05
Ilaria (F), born 17/08/09

Present Position (1): Staff Research Scientist, ICGEB, Trieste (currently P2/06, UN Conditions of Service).

Present Position (2): Contract Professor at the University of Trieste to teach the Molecular Medicine module at 5th year Biotechnology students.

Work Address: Molecular Pathology Group,
ICGEB, Trieste
Padriciano 99, 34149, Trieste, Italy.
Tel. (work): +39-40-3757316.
Fax: +39-40-226555.
e-mail: buratti@icgeb.org

HIGH SCHOOL AND UNIVERSITY EDUCATION

1979-1984. Raynes Park High School, Raynes Park, London (UK). A level examinations: Biology (grade B), Physics (grade B), Chemistry (grade B) and General Studies (grade A).

1984-1989. Degree in Biology at the University of Trieste, Italy. Degree thesis: "HMGI proteins in the Lewis lung carcinoma" (maximum marks: 110/110).

1989-1993. Biochemistry PhD student at the Department of Biochemistry, Biophysics, and Macromolecular Chemistry (BBCM) of the University of Trieste. PhD thesis: "Study of two groups of nuclear proteins".

1994. July/Sept. Pathology Consultant for UNIDO (United Nation Industrial Development Organization) assigned to ICGEB, Trieste, Italy.

1st Sept.1994 PhD thesis defended in Rome (Italy).

1994-1996. Post doctoral fellow at ICGEB.

1996-1998. Research Grant from the Istituto Superiore della Sanita', (ISS) Rome, Italy (AIDS Research Project).

since Aug.1998 ICGEB Staff Research Scientist (service category: Professional)

since Sept.2009 Contract Professor at the University of Trieste to teach the Molecular Medicine Course to Bsc. Biotechnology degree students.

Languages: Italian (native), English (spoken and written)

Computer: extensive use of molecular biology programs for MacIntosh computers. Courses: **Computer applications in Molecular Biology**, practical course held by Prof. Douglas Brutlag, Stanford University, USA. ICGEB, Trieste (Italy), 13-14 July 1992.

Student supervision:

Italian B.Sc.

- a) Daniel Gherbassi. Thesis Title: "Regolazione dello splicing alternativo dell'esone EDA della fibronectina murina: importanza della struttura secondaria dell'RNA". Corso di Laurea in Biologia Academic Year 1998-1999.
- b) Antonia Brindisi. Thesis Title: "Identificazione di proteine nucleari che legano TDP-43: un nuovo regolatore dello splicing alternativo dell'esone 9 nel gene CFTR". Corso di Laurea in Biologia. Academic year: 2000-2001
- c) Luca Del Turco. Thesis Title: "Analisi mutazionale di differenti regioni del dominio II del virus dell'epatite C e la loro influenza sulla capacita' trascrizionale dell'IRES". Corso di Laurea in Biologia. Academic year: 2001-2002
- d) Maurizio Giombi. Thesis Title: "Studio dell'interazione di TDP-43 con le hnRNP A/B e conseguente ruolo nello splicing alternativo dell'esone 9 nel gene CFTR". Corso di Laurea in Biologia. Academic year: 2001-2002.
- e) Greta de Prato. Thesis Title: "Caratterizzazione dell'Intronic Splicing Silencer nell'esone 9 del gene CFTR". Corso di Laurea Specialistica in Biotechnologie Mediche. Academic Year: 2004-2005.
- f) Valentina Carmineo. Thesis Title: "Espressione di varianti patologiche della proteina nucleare TDP-43". Corso di Laurea in Biologia. Academic year: 2007-2008.
- g) Alice Paulitti. Thesis Title: "Caratterizzazione della regione C-terminale di TDP-43 responsabile del legame con le proteine hnRNP" Corso di laurea in Biotechnologie Mediche. Academic Year 2008-2009.

PhD Thesis supervision (SISSA and Open University):

- a) Federico Odreman (SISSA, Trieste). 2001. Thesis title: Mutational analysis of the hepatitis C Virus Internal Ribosome Entry Site and its implications in translation initiation.
- b) Antonia Brindisi (Open University). 2006. Thesis title: Characterization of CFTR exon 9 splicing inhibition mediated by pre-mRNA interaction with TDP-43.
- c) Paola Zago (Open University). 2009. Thesis title: Investigating Multiple Roles of RNA Secondary Structure, Trans-Acting Factors and Evolutionary Pressure on the Splicing Regulation of Fibronectin EDA Exon.
- d) Ashish Dhir (Open University), 2009. Thesis title: Investigating The Role of RNA Secondary Structure on the Splicing Regulation of Pseudoexon Inclusion Events.

e) Ariful Haque (Open University), 2010. Thesis title: Characterization of a Composite Exonic Regulatory Element of Splicing (CERES) in CFTR exon 12: functional properties and evolutionary constraints.

f) Monica Passoni (Open University), 2011. Thesis title: Dinucleotide TG repeats and 5' splice site definition.

Teaching activities:

a) yearly lessons on pre-mRNA splicing and mRNA translation as part of the Course in Molecular Medicine (Biotechnology degree course) held at the University of Trieste. Academic Years: 2005- 2008. **Since 2009, I have officially become Contract Professor at the University of Trieste to teach the Molecular Medicine teaching module for the 5th year Biotechnology students.**

b) examiner for the PhD exam commissions at the University of Udine and Nova Goriza (Slovenia).

c) yearly lectures on pre-mRNA splicing at the Erasmus Week "Regulation of Gene Expression" organized at the University of Trieste as part of the Course in Functional Genomics (a course held in conjunction with the French Universities Paris Diderot-Paris 7 and Paris Descartes-Paris 5). Academic Years: 2007-present.

d) yearly lessons at the PhD Introductory Course of ICGEB on various topics such as mRNA translation, genetic engineering, and pre-mRNA splicing. Years: 2004-present.

Other Experience and Professional Membership

Routine Paper Reviews from:

American Journal of Human Genetics

Human Molecular Genetics

Human Mutation

Nucleic Acids research

PLoS ONE

Since 2011: Academic Editor (member of the Editorial Board) of PLoS ONE

PUBLICATIONS (95)

2011

1) **DBASS3 and DBASS5: databases of aberrant 3' and 5' splice sites.**

Buratti E., Chivers M., Hwang G., and Vorechovsky I.
Nucleic Acids Research, 2011, 39: D86-91

2) **PRO-MINE: A bioinformatics repository and analytical tool for TDP-43 mutations.**

Pinto S., Vlahoviceck K., Buratti E.
Human Mutation, 2011, 32:E1948-1958.

3) **Splicing mutations in Glycogen Storage Disease Type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes.**

Zampieri S.*, Buratti E.*, Dominissini S., Montalvo AL, Pittis MG, Bembi B., Dardis A.
European Journal of Human Genetics, 2011, 19: 422-431.

*these authors contributed equally to this work.

4) **TDP-43 regulates its mRNA levels through a negative feedback loop.**

Ayala Y.M.*, De Conti L.*, Vázquez S.E.A.*, Dhir A.*, Romano M., D'Ambrogio A., Tollervey J., Ule J., Baralle M., Buratti E., Baralle F.E.
EMBO Journal, 2011, 30:277-288.

*these authors contributed equally to this work.

5) **Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration.**

Budini M., Baralle F.E., Buratti E.
Current Alzheimer Research, 2011, 8:237-245.

6) **TDP-43 regulates Drosophila Neuromuscular Junctions growth by modulating Futsch/MAP1B levels and synaptic microtubules organization.**

Godena V.K., Romano G., Romano M., Appocher C., Klima R., Buratti E., Baralle F.E., Feiguin F.
PLoS ONE, 2011, 6: e17808.

7) **InTRONs in biotech.**

Skoko N., Baralle M., Tisminetzky S., Buratti E.
Molecular Biotechnology, 2011, 48:290-297.

8) **Alternative splicing of tumor-promoting *Cyr61* is regulated by hTRA2- β 1 and acidosis.**

Hirschfeld M., Jaeger M., Buratti E., Stuani S., Grueneisen J., Gitsch G., Stickeler E.
Human Molecular Genetics, 2011, 20: 2356-2365.

9) **TDP-43: New aspects of autoregulation mechanisms in RNA binding proteins and their connection with human disease.**

Buratti E., Baralle F.E.
FEBS Journal, 2011, 278: 3529.

10) **TDP-43: Overview of the series.**

Baralle F.E., Buratti E.,
FEBS Journal, 2011, , 278: 3530-3538.

11) **Evolutionary connections between coding and splicing regulatory regions in the fibronectin EDA exon.**

Zago P.*, Buratti E.*, Stuani C., and Baralle F.E.
Journal of Molecular Biology, 2011, 411: 1-15.

*these authors contributed equally to this work.

12) **TDP-43 autoregulation: implications for disease.**

Budini E. and Buratti E.

Journal of Molecular Neuroscience, 2011, in press.

13) **TDP-43 and FUS in ALS/FTLD: will common pathways fit all?**

Buratti E.

Neurology, 2011, in press.

2010

1) **Functional properties and evolutionary splicing constraints on a Composite Exonic Regulatory Element of Splicing (CERES) in CFTR exon 12.**

Haque A.*, Buratti E.*, and Baralle F.E.

Nucleic Acids Research, 2010, 38: 647-659.

*these authors contributed equally to this work.

2) **Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies.**

Dhir A. and Buratti E.

FEBS Journal, 2010, 277: 841-855.

3) **The intronic splicing code: multiple factors involved in ATM pseudoexon definition.**

Dhir A., Buratti E., van Santen M.A., Lührmann R., and Baralle F.E.

EMBO Journal, 2010, 29: 749-760.

4) **TDP-43 in skeletal muscle of patients affected with amyotrophic lateral sclerosis.**

Sorarù G., Orsetti V., Buratti E., Baralle F.E., Cima V., Volpe M., D'Ascenzo C., Palmieri A., Koutsikos K., Pegoraro E., and Angelini C.

Amyotrophic Lateral Sclerosis, 2010, 11: 240-243.

5) **Nuclear factor TDP-43 can affect selected miRNA levels.**

Buratti E., De Conti L., Stuani C., Romano M., Baralle M. and Baralle F.E.

FEBS Journal, 2010, 277, 2268-2281

6) **Neurons don't appreciate FUSsing in the cytoplasm.**

Buratti E. and Baralle F.E.

EMBO Journal, 2010, 29: 2769-2771.

7) **TARDBP mutations in Frontotemporal Lobar Degeneration: frequency, clinical features, and disease course.**

Borroni B., Archetti S., Del Bo R., Papetti A., Buratti E., Bonvicini C., Agosti C., Cosseddu M., Turla M., Di Lorenzo D., Comi G.P., Gennarelli M. and Padovani A.

Rejuvenation Research, 2010, 13: 509-517.

8) **Novel roles of U1snRNP in alternative splicing regulation.**

Buratti E. and Baralle D.

RNA Biology, 2010, 7: 412-419.

9) **The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation.**

Buratti E. and Baralle F.E.

RNA Biology, 2010, 7: 420-429.

10) **Neurotoxic effects of TDP-43 overexpression in *C. elegans*.**

Ash P.E.A., Zhang Y-j., Roberts C.M., Saldi T., Hutter H., Buratti E., Petrucelli L., Link C.D.

Human Molecular Genetics, 2010, 19: 3206-3218.

11) **CELF proteins regulate CFTR pre-mRNA splicing: essential role of the divergent domain of ETR-3.**

Dujardin G., Buratti E., Charlet-Berguerand, N., Martins de Araujo M., Mbopda A., Le Jossic-Corcus C., Pagani F.,

Ferec C. and Corcos L.
Nucleic Acids Research, 2010, 38: 7273-7285.

12) Sam68 regulates epithelial to mesenchymal transition through alternative splicing-activated NMD of the SF2/ASF proto-oncogene.

Valacca C., Bonomi S., Buratti E., Pedrotti S., Baralle F., Sette C., Ghigna C., and Biamonti G.
Journal of Cell Biology, 2010, 191: 87-99.

2009

1) Improving human beta interferon production in mammalian cell lines by insertion of an intronic sequence within its naturally uninterrupted gene.

Zago P., Baralle M., Ayala Y.M., Skoko N, Zacchigna S., Buratti E* and Tisminetzky S.
Biotechnology and Applied Biochemistry, 2009, 52: 191-198.

*corresponding author

2) Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: Identification of 6 novel alleles.

Zampieri S., Filocamo M., Buratti E., Stroppiano M., Vlahovicek K., Rosso N., Bignulin E., Regis R., Carnevale F., Bembi B., and Dardis A.
Neurogenetics, 2009, 10: 49-58.

3) High frequency of TARDBP gene mutations in Italian patients with Amyotrophic Lateral Sclerosis.

Corrado L.*, Ratti A.*, Gellera C., Buratti E., Castellotti B., Carlomagno Y., Ticozzi N., Mazzini L., Testa L., Taroni F., Baralle F.E., Silani V., D'Alfonso S.

*these authors contributed equally to this work

Human Mutation, 2009, 30: 688-694.

4) Ab initio prediction of mutation-induced cryptic splice-site activation and exon skipping.

Divina P., Kvitkovicova A., Buratti E., Vorechovsky I.
European Journal Human Genetics, 2009, 17: 759-765.

5) Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTL-D are recapitulated in SH-SY5Y cells.

Nonaka T., Arai T., Buratti E., Baralle F.E., Akiyama H., Hasegawa M.
FEBS Letters, 2009, 583: 394-400.

6) Low U1snRNP dependence at the NF1 exon 29 donor splice site.

Raponi M., Buratti E., Dassie E., Upadhyaya M., Baralle D.
FEBS Journal, 2009, 276: 2060-2073.

7) Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.

Zhang Y.-J., Xu Y.-F., Cook C., Gendron T., Roettges P., Link C.D., Lin W.-L., Tong J., Catanedes-Casey M., Ash P., Gass J., Rangachari V., Buratti E., Baralle F., Golde T., Dickson D.W., and F. Petrucelli
Proceedings National Academy of Science (USA), 2009, 106: 7607-7612.

8) Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo.

D'Ambrogio A.*, Buratti E.*, Stuani C., Guarnaccia C., Romano M., Ayala Y.M. and Baralle F.E.
Nucleic Acids Research, 2009, 37: 4116-4126.

*these authors contributed equally to this work

9) Missed Threads - The impact of pre mRNA splicing defects in clinical practice.

Baralle D., Lucassen A., and Buratti E.
EMBO Reports, 2009, 10: 810-816.

10) The molecular links between TDP-43 dysfunction and neurodegeneration.

Buratti E., Baralle F.E.
Advances in Genetics, 2009, 66:1-34.

11) Mutation within *TARDBP* leads to Frontotemporal Dementia without motor neuron disease.

Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., Papetti A.,
Stuani C., Di Luca M., Gennarelli M., Padovani A.
Human Mutation, 30: E974-E983.

12) TDP-43 is recruited to stress granules in conditions of oxidative insult.

Colombrita C., Zennaro E., Fallini C., Weber M., Sommacal A., Buratti E., Silani V., Ratti A.
Journal of Neurochemistry, 2009, 111:1051-1061.

2008

1) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease.

Buratti E. and Baralle F.E.
Frontiers in Bioscience, 2008, 13: 867-878.

2) TDP-43 mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Bellerocche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., and Shaw C.E.
Science, 2008, 319: 1668-1672.

3) Structural and functional characterization of the 5' region of subgenomic RNA5 of Cucumber mosaic virus.

Thompson, J.R., Buratti E., de Wispelaere, M., and Tepfer, M.
Journal of General Virology, 2008, 89: 1729-1738.

4) Phosphorylated TDP-43 in frontotemporal lobar degeneration and ALS

Hasegawa M., Arai T., Nonaka T., Kametani F., Yoshida M., Hashizume Y., Beach T.G., Buratti E., Baralle F., Morita M., Nakano I., Oda T., Tsuchiya K., and Akiyama H.
Annals of Neurology, 2008, 64: 60-70.

5) The secondary structure of the HIV-1 transcript modulates viral splicing and infectivity.

Jablonski J.A.*, Buratti E.*, Stuani C., and Caputi M.
Journal of Virology, 2008, 82: 8038-8050.
*these authors contributed equally to this work

6) The pathological splicing mutation c.6792C>G in *NFI* exon 37 causes a change of tenancy between antagonistic splicing factors.

Skoko N.*, Baralle M.*, Buratti E., and Baralle F.E.
FEBS letters, 2008, 582: 2231-2236.
*these authors contributed equally to this work

7) Abnormal phosphorylation of Ser409/410 of TDP-43 in FTL-D and ALS.

Inukai Y., Nonaka T., Arai T., Yoshida M., Hashizume, Y., Beach T.G., Buratti E., Baralle F.E., Akiyama H., Hisanaga S.I., Hasegawa M.
FEBS Letters, 2008, 582: 2899-2904.

8) Structural determinants of the cellular localization and shuttling of TDP-43.

Ayala Y.M.*, Zago P.*, D'Ambrogio A., Xu Y-F., Petrucelli L., Buratti E. and Baralle F.E.
Journal of Cell Science, 2008, 121: 3778-3785.
*these authors contributed equally to this work

9) Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1.

Raponi M., Buratti E., Llorian M., Stuani S., Smith C.W.J., Baralle D.
FEBS Journal, 2008, 275: 6101-6108.

2007

1) SR protein mediated inhibition of CFTR exon 9 inclusion. Molecular characterization of the Intronic Splicing Silencer

Buratti E., Stuani S., De Prato G., and Baralle F.E.
Nucleic Acids Research, 2007, 35: 4359-4368.

2) Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Buratti E., Chivers M., Kralovicova J., Romano M., Baralle M., , Krainer A.R., Vorechovsky I.
Nucleic Acids Research, 2007, 35: 4250-4263.

3) RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events.

Buratti E.*, Dhir A.*, Lewandowska M.A., and Baralle F.E.
Nucleic Acids Research, 2007, 35: 4369-4383.

*these authors contributed equally to this work

4) Progranulin mediates caspase-dependent cleavage of TDP-43.

Zhang Y.-J., Xu Y.-F., Dickey C., Buratti E., Baralle F., Bailey R., Pickering-Brown S., Dickson D., Petrucelli, L.
Journal of Neuroscience, 27: 10530-10534.

2006

1) Cryptic splice site usage in exon 7 of the human fibrinogen B β -chain gene is regulated by a naturally silent SF2/ASF binding site within this exon.

Spena S., Tenchini M.L., and Buratti E.
RNA, 2006, 12: 948-958.

2) Characterization of two novel GBA mutations causing Gaucher disease that lead to aberrant RNA species by using functional splicing assays

Dominissini S., Buratti E., Bembi B., Baralle M. and Pittis M.G.
Human Mutation, 2006, 27: 119.

3) Mutation profile of the GAA gene in 40 Italian patients with late onset Glycogen Storage Disease type II.

Montalvo A.L.E., Bembi B., Donnarumma M., Filocamo M., Parenti G., Rossi M., Merlini L., Buratti E., De Filippi P., Dardis A., Stroppiano M., Ciana G., and Pittis M.G.
Human Mutation, 2006, 27:999-1006.

4) NF1 mRNA biogenesis: Effect of the genomic milieu in splicing regulation of the NF1 exon 37 region.

Baralle M., Skoko N., Knezevich A., De Conti L., Motti D., Bhuvanagiri M., Baralle D., Buratti E., and Baralle F.E.
FEBS Letters, 2006, 580: 4449-4456.

5) Defective splicing, disease, and therapy: searching for master checkpoints in exon definition.

Buratti E., Baralle M., and Baralle F.E.
Nucleic Acids Research, 2006, 34:3494-3510

2005

1) TDP-43 binds hnRNP A/B through its C-terminal tail: an important region for the inhibition of CFTR exon 9 splicing.

Buratti E.*, Brindisi A.*, Giombi M., Tisminetzky S., Ayala Y.M. and Baralle F.E.
Journal Biological Chemistry, 2005, 280: 37572-37584.

*these authors contributed equally to the work

2) Depletion of TDP-43 overrides the need for exonic and intronic splicing enhancers in the Human Apo AII gene.

Mercado P.A., Ayala Y.M., Buratti E., Romano M. and Baralle F.E.
Nucleic Acids Research, 2005, 33:6000-6010.

3) Induction of Murine mucosal CCR5-reactive antibodies as anti-HIV strategy.

Barassi C., Soprana E., Pastori C., Longhi R., Buratti E., Lillo F., Marenzi C., Lazzarin A., Siccardi A.G., Lopalco L.
J.Virol., 2005, 79: 6848-6858.

4) Another step forward for SELEXive splicing

Buratti E., and Baralle F.E.
Trends in Molecular Medicine, 2005, 11:5-9.

5) A T3 allele in the CFTR gene exacerbates exon 9 skipping in vas deferens and epididymal cell lines and is associated with Congenital Bilateral Absence of Vas Deferens (CBAVD).

Disset A., Michot C., Harris A., Buratti E., Claustres M. and Tuffery-Giraud S.
Human Mutation, 2005, 25: 72-81.

6) Human, Drosophila, and C. elegans TDP43: Nucleic Acid Binding Properties and Splicing Regulatory Function.

Ayala Y.M., Pantano S., D'Ambrogio A., Buratti E., Brindisi A., Marchetti C., Romano M., and Baralle F.E.
Journal Molecular Biology, 2005, 348: 575-588.

2004

1) Influence of RNA secondary structure on the pre-mRNA splicing process.

Buratti E. and Baralle F.E.
Molecular and Cellular Biology, 2004, 24: 10505-10514.

2) hnRNP H binding at the 5' splice site correlates with the pathological effect of intronic mutations in the NF-1 and TSH β genes.

Buratti E.*, Baralle M. *, De Conti L., Baralle D., Romano M., Ayala Y.M., and Baralle F.E.
Nucleic Acids Research, 2004, 32: 4224-4236.

*these authors contributed equally to the work

3) Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: A functional link with disease penetrance.

Buratti E., Brindisi A., Pagani F. and Baralle F.E.
American Journal of Human Genetics, 2004, 74:1322-1325.

4) An intronic polypyrimidine rich element downstream of the donor site modulates CFTR exon 9 alternative splicing.

Zuccato E., Buratti E., Stuani C., Baralle F.E., and Pagani F.
Journal of Biological Chemistry, 2004, 279:16980-16988.

5) RNA folding affects the recruitment of SR proteins by mouse and human ESE elements in the fibronectin EDA exon.

Buratti E., Muro A.F., Giombi M., Gherbassi D. Iaconcig S. and Baralle F.E.
Molecular and Cellular Biology, 2004, 24:1387-1400.

6) Ribosomal protein S1 specifically binds to the 5' Untranslated Region of the Pseudomonas aeruginosa Stationary-Phase Sigma factor rpoS mRNA in the Logarithmic Phase of Growth.

Sevo M., Buratti E., Venturi V.
Journal of Bacteriology, 2004, 186: 4903-4909.

2003

1) Can a patch in skipped exons make the pre-mRNA splicing machine run better?.

Buratti E., Pagani F., and Baralle F.E.
Trends in Molecular Medicine, 2003, 9: 229-232.

2) Missense, nonsense and neutral mutations define juxtaposed regulatory elements of splicing in CFTR Exon 9.

Pagani F., Buratti E., Stuani C., and Baralle F.E.
Journal Biological Chemistry, 2003, 29: 26580-26588.

2002

1) Regulation of 3' splice site selection in the 844ins68 polymorphism of cystathionine β -synthase gene.

Romano M., Marcucci R., Buratti E., Ayala Y.M., Sebastio G., and Baralle F.E.
Journal Biological Chemistry, 2002, 277: 43821-43829.

2) A new type of mutation causes a splicing defect in ATM.

Pagani F., Buratti E., Stuani T., Bendix R., Dörk T. and Baralle F.E.
Nature Genetics, 2002, 30: 426-429.

2001

1) Nuclear factor TDP-43 and SR proteins promote *in vitro* and *in vivo* CFTR exon 9 skipping.

Buratti E., Dörk T., Zuccato E., Pagani F., Romano M., Baralle F.E.
EMBO Journal 2001, 20: 1774-1784.

2) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Buratti E. and Baralle F.E.
Journal of Biological Chemistry 2001, 276: 36337-36343.

3) Mutational analysis of the different bulge regions of the HCV domain II and their influence on IRES translational ability.

Odreman-Macchioli F.E., Baralle F.E. and Buratti E.
Journal of Biological Chemistry 2001, 276: 41648-41655.

2000

1) Splicing factors induce CFTR exon 9 skipping through a non evolutionary conserved intronic element.

Pagani F., Buratti E., Stuani C., Romano M., Zuccato E., Niksic M., Giglio L., Faraguna D., Baralle F.E.
Journal of Biological Chemistry 2000, 275, 21041-21047.

2) Influence of correct secondary and tertiary RNA folding on the binding of cellular factors to the HCV IRES.

Odreman-Macchioli F.E., Tisminetzky S.G., Zotti M., Baralle F.E. and Buratti E.
Nucleic Acids Research 2000, 28: 875-885.

3) Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of Human Immunodeficiency Virus Type 1: its deletion leads to a strong neutralizing response.

Cleveland S.M., Buratti E., Jones T.D., North P., Baralle F., McLain L., McInerney T., Durrani Z., Dimmock N.J.
Virology 2000, 266:66-78

1999

1) Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9.

Niksic M., Romano M., Buratti E., Pagani F., Baralle F.E.
Human Molecular Genetics 1999, 8:2339-2349.

2) Regulation of fibronectin EDA exon alternative splicing: possible role of RNA secondary structure for enhancer display.

Muro A.F., Caputi M., Pariyarath R., Pagani F., Buratti E. and Baralle F.E.
Molecular and Cellular Biology, 1999, 19: 2657-2671.

3) Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites.

Ramasamy R., Yasawardena S., Kanagaratnam R., Buratti E., Baralle F.E. and M.S. Ramasamy.
Parasite Immunology, 1999, 21:397-407.

4) Mammalian cell expression of malaria merozoite surface proteins and experimental DNA and RNA immunisation.

Ramasamy R., Yasawardena S.G., Kanagaratnam R., Buratti E., Baralle F.E. and M.S. Ramasamy.
Biochimica Biophysica Acta, 1999, 1453: 1-13.

1998

1) Functional analysis of the interaction between HCV 5'UTR and putative subunits of eukaryotic translation initiation factor eIF3.

Buratti E., Tisminetzky S.G., Zotti M. and F. E. Baralle
Nucleic Acids Research, 1998, 26: 3179-3187.

2) Localization of the different Hepatitis C Virus core gene products expressed in COS-1 cells.

Buratti E., Baralle F.E., and Tisminetzky S.G.
Cellular and Molecular Biology (Noisy-le-grand), 1998, 44: 505-512.

3) The neutralizing antibody response against a conserved region of HIV-1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope.

Buratti E., McLain L., Tisminetzky SG., Cleveland SM., Dimmock N.J. and Baralle F.E..
Journal of General Virology, 1998, 79: 2709-2716.

1997

1) In vivo translational efficiency of different Hepatitis C Virus 5' UTRs.

Buratti E., Gerotto M., Pontisso P., Alberti A., Tisminetzky S. G., and Baralle F. E.
FEBS Letters, 1997, 411: 275-280.

2) A neutralizing monoclonal antibody previously mapped exclusively on HIV-1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.

Buratti E., Tisminetzky S. G., D'Agaro P., and Baralle F.E.
Journal of Virology, 1997, 71: 2457-2462.

3) Improved reactivity of HCV core protein epitopes using a conformational antigen presenting system.

Buratti E., Di Michele M., Song P., Monti-Bragadin C., Scodeller E. A., Baralle F. E. and Tisminetzky S. G.
Clinical and Diagnostic Laboratory Immunology, 1997, 4:117-121.

4) V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.

Schiappacassi M., Buratti E., D'Agaro P., Ciani L, Scodeller E. S., Tisminetzky S.G. and Baralle F.E.
Journal of Virological Methods 1997, 63: 121-127.

1996

1) Conformational display of two neutralizing epitopes of HIV-1 gp41 on the Flock House Virus capsid protein.

Buratti E., Tisminetzky S.G., Scodeller E.S., and Baralle F.E.
Journal of Immunological Methods, 1996, 197: 7-18.

1995

1) Differential expression of a novel proline rich homeobox (Prh) in human hematolymphopoietic cells.

Manfioletti G., Gattei V., Buratti E., Rustighi A., De Iulius A., Aldinucci D., Goodwin G.H., and A. Pinto.
Blood, 1995, 85: 1237-1245.

1992

1) Identification of a novel vertebrate homeobox gene expressed in haematopoietic cells.

Crompton M. R., Bartlett T.J., Macgregor A.D., Manfioletti G., Buratti E., Giacotti V. and G. H. Goodwin.
Nucleic Acids Research, 1992, 20: 5661-5667.

2) Molluscan sperm proteins: Ensis minor.

Giacotti V., Buratti E., Santucci A., Neri P., and Crane-Robinson C.
Biochimica Biophysica Acta, 1992, 1119: 296-302.

1991

1) cDNA cloning of the HMGI-C Phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes.

Manfioletti G., Giacotti V., Bandiera A., Buratti E., Sautiere P., Cary P., Crane-Robinson C., Coles B., and Goodwin G.H.

Nucleic Acids Research, 1991, 19: 6793-6797.

2) Comparison of the multiple forms of the HMGI proteins in rodent and human cells: identification of human HMGI-C.

Giacotti V., Bandiera A., Buratti E., Fusco A., Marzari R., Coles B. and G. H. Goodwin.

European Journal of Biochemistry, 1991, 198: 211-216.

1989

1) Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures.

Giacotti V., Buratti E., L. Perissin, S. Zorzet, A. Balmain, G. Portella, A. Fusco, and G. H. Goodwin.

Experimental Cell Research, 1989, 184: 538-545.

Book Chapters/Others

1) Immunoreactivity of chimeric proteins carrying the HIV-1 epitope IGPGRAF: Conformation and Antigenicity.

Tisminetzky S.G., Scodeller E.A., Schiappacassi M., Buratti E., Chen Y., and Baralle F.E.

Current Developments in Animal Virology

Jaamel S. and Wagner E.K. (Eds.) pp. 363-374 (1996)

Oxford & IBH Publishing Co. Pvt. Ltd., New Delhi, India and Science Publishers Inc., Lebanon N.H., USA.

2) Splicing in the RNA World.

Buratti E., Romano M., Baralle F.E.

Alternative pre-mRNA splicing: Theory and Protocols

Stamm S., Smith C.W., Lurhmann R. (Eds.) pp. **XXX** (2011)

Wiley-VCH, Weinheim

3) Splicing and Disease.

Buratti E., Baralle F.E.

Alternative pre-mRNA splicing: Theory and Protocols

Stamm S., Smith C.W., Lurhmann R. (Eds.) pp. XXX (2011)

Wiley-VCH, Weinheim

4) Identification of proteins bound to RNA.

Buratti E.

Alternative pre-mRNA splicing: Theory and Protocols

Stamm S., Smith C.W., Lurhmann R. (Eds.) pp. XXX (2011)

Wiley-VCH, Weinheim

5) Exon skipping mutations in Neurofibromatosis.

Buratti E., Baralle D.

Exon Skipping

Aartsma-Rus, **in press.**

6) TDP-43.

Buratti E.

Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias

Strong M. (Ed.)

Oxford University Press, **in press.**

7) Protein splicing

Baralle M. and Buratti E.

Encyclopedia of Genetics, 2nd edition

Mitchell S. (Ed.)

Elsevier, **in press.**

8) Alternative Splicing: Role of Pseudoexons in Human Genetic Disease

Buratti E.

eLS 2011,

John Wiley & Sons, Ltd: Chichester

[DOI: 10.1002/9780470015902.a0023579]